Prospecto: Information for the User
Glatiramero Viatris 40 mg/ml Injectable Solution in Pre-filled Syringe
glatiramero, acetate
Read this prospectus carefully before starting to use this medication because it contains important information for you.
1.What is Glatiramero Viatris and for what it is used
2.What you need to know before starting to use Glatiramero Viatris
3.How to use Glatiramero Viatris
4.Possible adverse effects
5.Storage of Glatiramero Viatris
6.Contents of the package and additional information
Glatiramero is a medicationused for the treatment of recurrent forms of multiple sclerosis (MS).It modifies the way the immune system of your body functions and is classified as an immunomodulator agent. It is believed that the symptoms of multiple sclerosis (MS) are produced by a defect in the immune system of the body. This produces areas of inflammation in the brain and spinal cord.
Glatiramero is used to reduce the number of times you experience MS attacks (relapses). It has not been shown to be effective if you have a form of MS that does not have relapses or almost no relapses. Glatiramero may have no effect on the duration of an MS attack, or how poorly you feel during an attack.
Do not use Glatiramero Viatris
Warnings and precautions
Consult your doctor or pharmacist before starting to use Glatiramero Viatris:
Glatiramero Viatris may cause severe allergic reactions, some of which can be potentially life-threatening.
These reactions can occur shortly after administration, even months or years after starting treatment, and even if you have not had any allergic reactions after previous administrations.
The signs and symptoms of allergic reactions may overlap with those of injection reactions. Your doctor will inform you about the signs of an allergic reaction.
Children
Glatiramero cannot be used in children under 18 years old.
Older patients
Glatiramero has not been specifically studied in older people. Consult your doctor about this.
Other medications and Glatiramero Viatris
Inform your doctor or pharmacistif you are using, have used recently, or may need to use any other medication.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor for guidance on using acetate of glatiramero during pregnancy.
Glatiramero can be used during pregnancy under the guidance of your doctor.
Limited human data showed no negative effects of acetate of glatiramero on newborns/breastfed infants. Acetate of glatiramero can be used during breastfeeding.
Driving and operating machinery
Glatiramero does not affect your ability to drive or operate machinery.
The recommended dose in adults is a pre-filled syringe (40 mg of glatiramer acetate), administered under the skin (subcutaneously) three times a week, with a separation of at least 48 hours between injections, for example, Monday, Wednesday, and Friday. It is recommended to administer the medication on the same days each week.
It is very important that the glatiramer injection is performed correctly:
The first time you use glatiramer, you will be given complete instructions and will be supervised by a doctor or nurse. They will be with you during the injection and for the next 30 minutes, only to ensure that you have no problems.
Usage Instructions
Read these instructions carefully before using Glatiramer Viatris.
Before the injection, make sure you have everything you need:
Wash your hands thoroughly with water and soap.
If you want to use an injection device to inject yourself, you can use the injection device for pre-filled syringes with Glatiramer Viatris. The injection device for pre-filled syringes is only approved for use with Glatiramer Viatris and has not been tested with other products. See the usage instructions provided with the injection device for pre-filled syringes.
Choose a place for the injectionwithin the areafollowing the diagrams.
There are seven possible injection areas on your body:
.
Area1: abdominal area (around the navel) Avoid the area 5cm around the navel.
Areas 2 and 3: Thighs (above the knees)
Areas 4, 5, 6, and 7: Upper back of the upper arms, end of the upper hips (below the waistline).
Within each injection area, there are several places where you can apply the injection. Choose a different place for the injection each day. This will reduce the possibility of irritation or pain at the injection site. Change the injection site within each area.Do not always use the same injection site.
Warning:do not inject in any area that is painful or discolored, or where you notice knots or firm lumps. It is recommended to have a schedule with the planned injection sites and note it in a diary. There are some areas on your body that may be difficult for self-injection (such as the back of your arm). If you want to use them, you may need help.
How to inject:
Figure 1Figure 2
If you think the effect of glatiramer is too strong or too weak, inform your doctor.
If you use more Glatiramer Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to use Glatiramer Viatris
Administer it as soon as you remember or have the opportunity to administer it, and avoid using it the next day. Do not administer a double dose to compensate for the missed doses. If possible, you should return to your usual administration schedule the following week.
If you interrupt treatment with Glatiramer Viatris
Do not stop using glatiramer without consulting your doctor.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Allergic reactions (hypersensitivity, anaphylactic reaction)
You may develop a severe allergic reaction to this medicine shortly after administration. This is a rare side effect. These reactions can occur months or years after starting treatment with Glatiramero Viatris, even if no allergic reactions have occurred after previous administrations.
If you notice any of the following sudden side effects,stop using glatiramero and immediately call your doctor or go to the nearest hospital emergency department:
Other reactions after injection (reaction immediately after injection)
Some people may experience one or more of the following symptoms minutes after the injection of glatiramero acetate. These usually do not pose a problem and disappear within 30 minutes.
However, if the following symptomslast more than 30 minutes, contact your doctor immediately, or go to the nearest hospital emergency department:
Liver problems
Liver problems or worsening of liver problems, including liver failure (which in some cases led to liver transplantation), can occur rarely with Glatiramero Viatris.
Contact your doctor immediately if you experience symptoms such as:
In general, the side effects reported by patients using glatiramero acetate 40 mg/ml three times a week were also reported by patients using glatiramero acetate 20 mg/ml (see the next list).
The following side effects have been described with glatiramero acetate:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 100 people)
Reporting of side effects
If you experience any type of side effect,consult your doctor or pharmacist, even if it is a side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use: https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store in refrigerator (between2°Cand8°C).
Pre-filled syringes of Glatiramero Viatris can be stored for up to one month outside the refrigerator, between15ºCand25ºC. This can only be done once. If after one month, pre-filled syringes of Glatiramero Viatris have not been used and are still in their original packaging, they must be returned to the refrigerator.
Do not freeze.
Store pre-filled syringes in the outer packaging to protect them from light.
Do not use this medication after the expiration date that appears on the label and on the cardboard box after “CAD”. The first two digits indicate the month and the last four digits indicate the year. The expiration date is the last day of the month indicated.
Dispose of any syringe that contains particles.
Medicines should not be thrown away through drains or in the trash. Ask your pharmacist how to dispose of the packaging and unused medicines. This will help protect the environment.
Composition ofGlatiramero Viatris
Appearance of the product and contents of the pack
Glatiramero Viatris is a sterile, transparent, colorless or slightly yellowish/brown solution.
If the solution contains particles, discard it and start again. Use a new syringe.
3 pre-filled syringes
12 pre-filled syringes
36 (3x12) pre-filled syringes
Only some pack sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
Synthon Hispania S.L.
Polígono Les Salines,C/Castelló 1
08830 Sant Boi de Llobregat (Barcelona)
Spain
Or
Synthon BV
Microweg 22
6545 CMNijmegen
Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland)with the following names:
Germany:CLIFT 40 mg/ml Injection Solution in a Pre-filled Syringe
Belgium:Glatiramyl 40 mg/ml, solution for injection in a pre-filled syringe
Cyprus:Glatiramer/Mylan 40mg/mL?usableliquidinapre-filledsyringe
Denmark:Copemyl
Spain:Glatiramero Viatris 40 mg/ml injection solution in a pre-filled syringe
Finland:Glatimyl 40 mg/ml injection solution, ready-to-use syringe
France:GLATIRAMER VIATRIS40 mg/ml, injection solution in a pre-filled syringe
Greece:Glatiramer / Mylan 40 mg/ml solution for injection, pre-filled syringe
Ireland:Brabio 40 mg/ml solution for injection, pre-filled syringe
Italy:COPEMYLPLUS
Norway:Copemyl 40 mg/ml injection solution, ready-to-use syringe
Netherlands:Glatirameeracetaat Viatris 40 mg/ml, solution for injection in a pre-filled syringe
Portugal:Acetato de glatirâmero Mylan
United Kingdom (Northern Ireland):Brabio 40 mg/ml solution for injection, pre-filled syringe
Sweden:Glatimyl 40 mg/ml injection solution, ready-to-use syringe
The reusable autoinjector is authorized in the member states of the European Economic Area with the following names:
Myject
Last review date of this leaflet:November 2024
More detailed and up-to-date information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.